|
|
International Clinical Trials
|
Acceleration of the integration of mobile health (mHealth) technologies into clinical trial operations is expected to be the catalyst for the adoption of disruptive research platforms with capabilities to overcome barriers in both clinically mature and emerging markets. While mHealth applications of smart devices, wearable biometric sensors, and telemedicine enable health monitoring, data collection, and patient communications have been around for some time. Despite this, their widespread use in clinical research should still be considered in its infancy. We continue to see the fast development of integrated mHealth platforms that have the potential to turn the traditional research model on its head – taking studies to patients rather than bringing patients into site-based studies. Powered by Big Data and connected across patients, researchers, and caregivers, emerging mHealth platforms will expand research participation, reduce costs, and integrate research with treatment in new models of personalised medicine based on real-world evidence.
The mHealth Disruption Four foundational trends are driving 21st century biomedical research:
- Globalisation is expanding drug development into the emerging markets of Africa, Asia, and Latin America
- Big Data is being harnessed to understand disease impacts at the population level and support evidence-based medical practice
- Real-world evaluation is extending the continuum from traditional randomised clinical trials to new research models that assess real-world outcomes
- Personalised medicine is advancing with targeted therapies tailored to smaller populations and the growth of patientcentric research
|
Read full article from PDF >>
|
 |
 |
 |
Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | |
|
|
 |
News and Press Releases |
 |
ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization
February 1, Utrecht, The Netherlands ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with type 1 Diabetes, is pleased to announce the appointment of Leo Toole as Chief Financial Officer and provides a corporate update on its expansion pathway of Kaleido into key European markets in 2023.
More info >> |
|

 |
White Papers |
 |
Choosing the Right CMO for HPAPI Manufacturing
AMRI
Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >> |
|
|